Science News
from research organizations

Increase in biomarker linked with increased risk of heart disease, heart failure, death

Date:
June 8, 2016
Source:
The JAMA Network Journals
Summary:
A new study examined the association of six-year change in high-sensitivity cardiac troponin T with incident coronary heart disease, heart failure and all-cause mortality.
Share:
FULL STORY

In a study published online by JAMA Cardiology, Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined the association of 6-year change in high-sensitivity cardiac troponin T with incident coronary heart disease, heart failure and all-cause mortality.

High-sensitivity cardiac troponin T (hs-cTnT), a protein that can be measured via a blood test, is a biomarker of cardiovascular risk and could be approved in the United States for clinical use soon. Cardiac troponin is critical to the clinical diagnosis of heart attack, particularly among symptomatic persons with chest pain. However, little is known about the implications of changes in hs-cTnT levels over time. This analysis included 8,838 participants from the Atherosclerosis Risk in Communities Study who were initially free of coronary heart disease (CHD) and heart failure (HF) and who had hs-cTnT measured twice, 6 years apart.

Of the participants (average age, 56 years; 59 percent female; 21 percent black), there were 1,157 CHD events, 965 HF events, and 1,813 deaths overall. Incident detectable hs-cTnT (baseline, <0.005 ng/ml; follow-up, ? 0.005 ng/ml) was independently associated with subsequent CHD, HF and death relative to an hs-cTnT level less than 0.005 ng/ml at both visits. Individuals with the most marked hs-cTnT increases (e.g. baseline, < 0.005 ng/ml; follow-up, ? 0.014 ng/ml) had significantly increased risks for CHD, HF and death. In persons with decreasing hs-cTnT levels (e.g., 6-year reductions >50 percent from baseline), there was also evidence suggestive of lower risk for outcomes compared with persons with stable or increasing concentrations.

"Our results indicate that 2 measurements of hs-cTnT appear to be better than 1 for characterizing risk and that large increases in hs-cTnT are particularly deleterious. Temporal change in hs-cTnT may help guide the preventive management of asymptomatic persons at risk for CHD and adults with stage A or B HF," the authors write.


Story Source:

Materials provided by The JAMA Network Journals. Note: Content may be edited for style and length.


Journal Reference:

  1. John W. McEvoy, Yuan Chen, Chiadi E. Ndumele, Scott D. Solomon, Vijay Nambi, Christie M. Ballantyne, Roger S. Blumenthal, Josef Coresh, Elizabeth Selvin. Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiology, 2016; DOI: 10.1001/jamacardio.2016.0765

Cite This Page:

The JAMA Network Journals. "Increase in biomarker linked with increased risk of heart disease, heart failure, death." ScienceDaily. ScienceDaily, 8 June 2016. <www.sciencedaily.com/releases/2016/06/160608120556.htm>.
The JAMA Network Journals. (2016, June 8). Increase in biomarker linked with increased risk of heart disease, heart failure, death. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2016/06/160608120556.htm
The JAMA Network Journals. "Increase in biomarker linked with increased risk of heart disease, heart failure, death." ScienceDaily. www.sciencedaily.com/releases/2016/06/160608120556.htm (accessed May 23, 2017).

RELATED STORIES